General Comments / Chat, page-7507

I still think the last 2-3 years counts towards the overall package, it just might not be the catalyst for sale or the reason a pharmaceutical company wants control of Zantrene, and as you said RAC220 is already completed, that has likely taken a large amount of time and effort and is going to be one of the main value drivers to be able to explore anything of commercial value to BP

I think the "under the radar" keep all the IP & info to ourselves strategy, but release every single piece of hiring & pre-clinical dish work was someone else's opinion or inexperience. Possibly treating it the same as a particular mining company receiving a low takeover, or treating it like a mining company diluting shareholders over years.

Yet to be seen if that is a smart way of running a biotech with 2 blockbuster opportunities & if we could have been much further ahead if we got some caliber on board 18-24 months ago post FTO.